Genomic Health Says International Markets, New Oncotype Indications are Key to Future Growth
August 11, 2010
Genomic Health Says International Markets, New Oncotype Indications are Key to Future Growth
While Genomic Health projects "more modest" growth for its legacy node-negative breast cancer business over the next year, newer markets in which the company is still working to secure reimbursement still represent a significant opportunity for expansion in the years ahead.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Deal with NewBridge Allows Genomic Health to Expand Oncotype DX into Africa, Middle East
August 13, 2012 / GenomeWeb Daily News - MDx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 13, 2012 / Pharmacogenomics Reporter - Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group
May 18, 2011 / Pharmacogenomics Reporter - After Profitable Year, Genomic Health to Invest in New Products, Overseas Market, Next-Gen Sequencing
February 16, 2011 / Pharmacogenomics Reporter - Genomic Health Updates Investors on Timeline for DCIS, Colon Cancer, Prostate Cancer Tests
September 29, 2010 / Pharmacogenomics Reporter